Cancer is one of the leading non-communicable diseases with highest mortality rates
worldwide. About half of all cancer patients receive radiation treatment in the course of their …

Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is activated by ligand
binding, overexpression, or mutation. It is well known for its tyrosine kinase-dependent …

Lung cancer still represents one of the most common and fatal neoplasm, accounting for
nearly 30% of all cancer-related deaths. Targeted therapies based on molecular tumor …

Nimotuzumab (N) is a humanized anti‐epidermal growth factor receptor monoclonal
antibody. This prospective, single‐armed, open label phase II study was conducted to …

Personalized patient-precise medicine is being gradually incorporated into clinical practice
for the treatment of non-small-cell lung cancer (NSCLC). The EGFR pathway has been …

Lung cancer varies between Caucasians and Asians. There have been differences recorded
in the epidemiology, genomics, standard therapies and outcomes, with variations according …

The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various
cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck …

We performed a meta-analysis to fully investigate the skin toxicities of anti-EGFR
monoclonal antibody (EGFR-MoAbs) in cancer patients. The relevant studies of the …

INTRODUCTION Racotumomab is a therapeutic vaccine based on a monoclonal anti-
idiotypic antibody developed by the Molecular Immunology Center in Havana, Cuba, that is …

Background Lung cancer is one of the most commonly diagnosed clinical diseases. IL-6 is a
multifunctional cytokine that is related to chemotactic factors and tumor biological …